Cecilia Lay

Title: Cecilia Lay: Innovator in Immune Regulation

Introduction

Cecilia Lay is a prominent inventor based in Brisbane, CA (US). She has made significant contributions to the field of immunology, particularly through her innovative work on antibodies that target the human CD200R1 receptor protein. With a total of 2 patents to her name, her research is paving the way for new therapeutic approaches.

Latest Patents

Cecilia Lay's latest patents focus on Anti-CD200R1 antibodies and methods of use thereof. The present disclosure provides binding proteins, such as antibodies and antigen-binding fragments, which specifically bind to human CD200R1 receptor protein (hu-CD200R1). These antibodies are capable of decreasing, inhibiting, and/or fully blocking immune regulatory effects mediated by hu-CD200R1. Furthermore, the disclosure outlines methods for using these antibodies and their compositions to treat diseases and conditions that respond to the modulation of immune regulatory functions mediated by CD200 binding to CD200R1.

Career Highlights

Cecilia Lay is currently employed at 23andMe, Inc., where she continues to advance her research in immunology. Her work is characterized by a commitment to developing innovative solutions that address complex health issues.

Collaborations

Cecilia collaborates with talented individuals such as Yu Chen and Jilean Beth Fenaux, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Cecilia Lay's contributions to the field of immunology through her patents and research at 23andMe, Inc. highlight her role as a leading inventor in the development of novel therapeutic strategies. Her work is essential in the ongoing quest to improve health outcomes through innovative science.